Leadership



Pioneering innovation with solid, experienced leadership





The ability to serve the cardiovascular market with state-of-the-art medical technology begins with solid, experienced leadership. Our Board of Directors and Executive Leadership are dedicated to collaborating with physicians to help get their patients back to what matters.

Executive Leadership Team

Scott Ward

Scott R. Ward

Chairman, President & CEO

Mr. Ward has been a member of our Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer.

Read More

Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC, and may provide limited advisory and consulting services to Sightline Partners in this capacity.

From 1981 to 2010, Mr. Ward was employed by Medtronic, Inc., and held a number of senior leadership positions. Mr. Ward was Senior Vice President and President of Medtronic’s CardioVascular business from May 2007 to November 2010. Prior to that he was Senior Vice President and President of Medtronic’s Vascular business from May 2004 to May 2007, Senior Vice President and President of Medtronic’s Neurological and Diabetes business, from February 2002 to May 2004, and was President of Medtronic’s Neurological business from January 2000 to January 2002. He was Vice President and General Manager of Medtronic’s Drug Delivery business from 1995 to 2000. Prior to that, Mr. Ward led Medtronic’s Neurological Ventures in the successful development of new therapies. Mr. Ward serves on the boards of several private companies. Until April 4, 2016, Mr. Ward was the Chairman of the Board of Creganna Medical. Mr. Ward served as a member of the Board of Surmodics, Inc., from September 2010 to March 2015.

Ryan

Ryan D. Egeland, MD PhD

Chief Medical Officer

Dr. Egeland joined CSI as Vice President of Medical Affairs in November of 2017. He has responsibilities providing global leadership, medical counsel and guidance to the organization on matters related to cardiovascular medicine, product and technology development, medical education, market development, quality assurance, clinical program design, clinical data analysis, regulatory affairs, and business development. Prior to joining CSI, Dr. Egeland held roles in marketing, medical affairs, and business development at Medtronic. Before this, he trained as a plastic and reconstructive surgeon at Northwestern Memorial Hospital, and received an MD with honors from Harvard Medical School. Dr. Egeland also holds a PhD in biochemistry and engineering from the University of Oxford, where he also completed a MBA as a Rhodes Scholar.

John Hastings

John M. Hastings

Vice President, Manufacturing & Operations

Mr. Hastings joined CSI as Vice President of Manufacturing and Operations in October of 2017. He is responsible for global Manufacturing, Operations, Supply Chain and Distribution. Prior to joining CSI, Mr. Hastings held several leadership roles at Abbott Laboratories (formerly St. Jude Medical), most recently as Sr. Site Director, Operations. Mr. Hastings served as Director of Engineering for American Medical Systems prior to his role with Abbott.

Jack

John (Jack) E. Nielsen

Vice President, Investor Relations & Corporate Communications

Mr. Nielsen joined CSI in March 2014 as Senior Director of Investor Relations and Corporate Communications and was promoted to Vice President in July 2018. He has over 20 years of investment and investor-related experience. Before joining CSI, Mr. Nielsen served as Director of Investor Relations at Xcel Energy and prior served as Director of Finance at Regis Corporation. Mr. Nielsen began his career as a securities analyst, covering a variety of high growth companies for Minneapolis-based investment banks. He has served as a member of the National Investor Relations Institute Twin Cities board of directors since 2007.

Jeffery Points

Jeffrey S. Points

Chief Financial Officer

Mr. Points joined CSI in September 2007 as Corporate Controller, became Senior Director and Controller in July 2013, Corporate Controller and Treasurer in January 2015, Vice President, Corporate Controller and Treasurer in May 2017 and was promoted to Chief Financial Officer in February 2018. From July 2005 to September 2007, Mr. Points was Assistant Controller at Empi, a manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. From January 1998 to July 2005, Mr. Points held various leadership positions at CliftonLarsonAllen, a national public accounting firm. Mr. Points also serves as a member of the Board of Directors for The Phoenix Residence, Inc.

Steve Rempe

Stephen J. Rempe

Vice President, Human Resources

Mr. Rempe joined CSI as Vice President of Human Resources in May 2019. He provides leadership in talent acquisition, organization development and effectiveness and talent development as we continue to scale our business. Mr. Rempe has over 20 years of human resources experience, most recently at Smiths Medical as Senior Vice President of Global Human Resources and prior, serving as Vice President of Global Talent Management at Boston Scientific. Mr. Rempe serves as a member of the Board of Trustees for The Works, a non-profit organization whose mission is to inspire the next generation of engineers, innovators and creative problem solvers.

Rhonda Rob

Rhonda J. Robb

Chief Operating Officer

Ms. Robb joined CSI as Chief Operating Officer in January 2018. Ms. Robb brings more than 30 years of medical device leadership to the company. Prior to CSI, she held several positions at Medtronic, most recently as Vice President and General Manager of the Heart Valve Therapies Business, including the transcatheter aortic valve business. In previous roles, Ms. Robb held leadership positions in Medtronic’s Coronary, Peripheral, and Cardiac Rhythm and Heart Failure businesses.

Alex Rosenstein

Alexander Rosenstein

General Counsel & Corporate Secretary

Mr. Rosenstein joined CSI in September 2014 as Corporate Legal and Compliance Counsel, became Corporate Secretary in November 2014, and was promoted to General Counsel in March 2015. From October 2005 to September 2014, Mr. Rosenstein was an attorney at Fredrikson & Byron, P.A., in Minneapolis. From 1998 to September 2005, he was an attorney practicing in New York City.

Sandra Sedo

Sandra M. Sedo

Chief Compliance Officer

Ms. Sedo joined CSI in June 2016. As Chief Compliance Officer, she is responsible for managing the company’s ethics and compliance program, including implementation of a Corporate Integrity Agreement. Ms. Sedo has over 25 years of experience as a lawyer and compliance professional, including being a partner at Dorsey & Whitney, LLP and as an in-house attorney and Deputy Compliance Officer at Medtronic. Ms. Sedo has worked exclusively in the medical device industry since 2005.

David Whitescarver

David S. Whitescarver

Vice President, Corporate Development & Intellectual Property

Mr. Whitescarver joined CSI as Vice President of Corporate Development and Intellectual Property in June 2017. Mr. Whitescarver brings more than 15 years of global leadership experience in the biomedical sector to the company, including senior leadership positions at Medtronic. Prior to this experience, Mr. Whitescarver led global teams at a Fortune 500 technology company and practiced law with a leading Wall Street firm.

Board of Directors

Scott Ward

Scott R. Ward

Chairman, President & CEO

Mr. Ward has been a member of CSI’s Board of Directors since 2013 and has served as Chairman since November 2014.

Read More

Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer.

Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC, and may provide limited advisory and consulting services to Sightline Partners in this capacity.

From 1981 to 2010, Mr. Ward was employed by Medtronic, Inc. and held a number of senior leadership positions. Mr. Ward was Senior Vice President and President of Medtronic’s CardioVascular business from May 2007 to November 2010. Prior to that he was Senior Vice President and President of Medtronic’s Vascular business from May 2004 to May 2007, Senior Vice President and President of Medtronic’s Neurological and Diabetes business, from February 2002 to May 2004, and was President of Medtronic’s Neurological business from January 2000 to January 2002. He was Vice President and General Manager of Medtronic’s Drug Delivery business from 1995 to 2000. Prior to that, Mr. Ward led Medtronic’s Neurological Ventures in the successful development of new therapies. Mr. Ward serves on the boards of several private companies. Until April 4, 2016, Mr. Ward was the Chairman of the Board of Creganna Medical. Mr. Ward served as a member of the Board of Surmodics, Inc., from September 2010 to March 2015.

Martha Aronson

Martha G. Aronson

Director

Ms. Aronson has been a member of CSI’s Board of Directors since February 2017.

Read More

Ms. Aronson served as Executive Vice President of Strategic Planning at Ecolab, Inc. from November 2015 to April 2016, and previously served as Ecolab’s Executive Vice President and President-Global Healthcare, from September 2012 to November 2015.  From 2010 to 2012, Ms. Aronson served as Senior Vice President and President, North America, of Hill-Rom Holdings, Inc. Before joining Hill-Rom, she served as Senior Vice President at Medtronic, Inc., from March 2008 to November 2009, and in various other domestic and international management positions with Medtronic, since 1991. She is also a director of Methode Electronics, Inc., CONMED Corporation and Clinical Innovations, LLC, and previously served as a director of Hutchinson Technology from 2010 to 2016, when it was acquired.

Ned Brown

Edward Brown

Director

Mr. Brown has been a member of CSI’s Board of Directors since February 2009 and was appointed as our Lead Independent Director in August 2016.

Read More

Mr. Brown currently serves as Managing Director at Five Arrows Capital Partners, an affiliate of the Rothschild Group. Mr. Brown was previously a Partner at Health Evolution Partners from 2010 to 2016, Managing Director at TPG Biotech from 2007 to 2009 and a Managing Director and co-founder of Healthcare Investment Partners, a private equity fund focused on healthcare investments, from 2004 to 2007.  Before Healthcare Investment Partners, Mr. Brown was a Managing Director in the healthcare group of Credit Suisse Group where he led the firm’s West Coast healthcare effort and was one of the senior partners responsible for the firm’s global life sciences practice. Mr. Brown currently serves on the board of Freedom Innovations, LLC and previously served on the board of Prolacta Biosciences, Inc., both private companies.  Mr. Brown previously served on the public company boards of Angiotech Pharmaceuticals, Inc., from January 2007 to June 2011, Oculus Innovative Sciences, Inc., from September 2005 to June 2008, and Replidyne, Inc., from May 2007 to February 2009, as well as several private company boards.

Billy Cohn

William Cohn, M.D.

Director

Dr. Cohn has been a member of CSI’s Board of Directors since February 2015.

Read More

Dr. Cohn is a Vice President of Medical Devices and Director of the Center for Device Innovation at Johnson & Johnson. He is also a Cardiothoracic Surgeon and a professor of Surgery at Baylor College of Medicine. Dr. Cohn is the Chief Medical Officer of BiVACOR USA, a privately-held medical device company.  He is also a venture partner with Santé Ventures, an early stage life science fund in Austin, Texas. Dr. Cohn has more than 90 U.S. patents granted or pending for medical device development.

Gus Lawlor

Augustine Lawlor

Director

Mr. Lawlor has been a member of CSI’s Board of Directors since February 2009.

Read More

Mr. Lawlor is the Managing Partner of HealthCare Ventures, LLC, where he was a Managing Director from 2000 to 2007.  Mr. Lawlor is also the Chief Operating Officer of Leap Therapeutics.  Mr. Lawlor was previously Chief Operating Officer of LeukoSite, Inc. and has also served as a management consultant with KPMG Peat Marwick.  Mr. Lawlor serves on the Board of Directors of Catalyst Biosciences, Inc., as well as several private companies.  He served on the Board of Directors of Human Genome Sciences, Inc., from March 2004 to August 2012, and the Board of Directors of Replidyne, Inc., from March 2002 to March 2009.

Erik Paulsen

Erik Paulsen

Director

Mr. Paulsen has been a member of CSI’s Board of Directors since July 2019.

Read More

From 2009 to 2019, he represented Minnesota’s Third Congressional District in the United States House of Representatives. During his tenure, Mr. Paulsen was a leading member on the House Ways and Means Committee, the House’s chief tax-writing body with broad jurisdiction over healthcare, economic and trade policy. Mr. Paulsen was also Chairman of Congress’ Joint Economic Committee, a unique House-Senate panel tasked with working alongside the President’s Council of Economic Advisors and the Federal Reserve Board to identify and address macroeconomic trends. Mr. Paulsen was co-chair of the bipartisan House Medical Technology Caucus, as well. Prior to his service in Congress, Mr. Paulsen was a member of the Minnesota State Legislature, where he served as House Majority Leader. Mr. Paulsen has over 16 years of business experience, including working as a business analyst at Target Corporation.

Stephen Stenbeck

Director

Mr. Stenbeck has been a member of CSI’s Board of Directors since November 2019.

Read More

A retired partner of Ernst & Young LLP (EY), Mr. Stenbeck brings 36 years of experience serving Fortune 500, midcap, and small cap public company audit clients in the medical device, retail, consumer products, distribution, airline and media and entertainment industries. Clients served as coordinating partner include several public medical device companies with significant international operations. Mr. Stenbeck also served for three years as a Professional Practice partner at EY consulting on technical accounting matters, and currently serves as a board member of Catholic Charities of St. Paul and Minneapolis.